The nonstaff members of IAS–USA Drug Resistance Mutations Group are volunteers and are not compensated for their role in overseeing the program. Listed below are the IAS–USA Drug Resistance Mutations Group members and their financial relationships with commercial interests within the past 12 months from the date of disclosure.


Members

Vincent Calvez, MD, PhD
Pierre et Marie Curie University
Pitié-Salpêtrière Hospital
Paris, France

Dr Calvez has served as an advisor or consultant to and has received re-search grants from Bristol-Myers Squibb, Johnson & Johnson, ViiV Healthcare, and Gilead Sciences, Inc, and is a founder of SkinDermic Pharma.

Francesca Ceccherini-Silberstein, PhD
University of Rome Tor Vergata
Rome, Italy

Dr Ceccherini-Silberstein has been a consultant to ViiV Healthcare, Bristol-Myers Squibb, and Merck Sharp & Dohme, Inc, and has received research grants from ViiV Health-care, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc.

Charlotte Charpentier, PharmD
Paris Diderot University
Bichat-Claude Bernard Hospital
Paris, France

Dr Charpentier serves as an advisor for ViiV Healthcare, Gilead Sciences, Inc, Janssen Therapeutics, and Merck Sharp & Dohme, Inc, and has received research grants from ViiV Healthcare.

Huldrych F. Günthard, MD
Professor of Infectious Diseases
University Hospital Zurich
Institute of Medical Virology
Zurich, Switzerland

Dr Günthard has served as a consultant to Merck & Co, Inc, ViiV Healthcare, Sandoz, Teva Pharmaceutical Industries, and Gilead Sciences, Inc, and has received research grants from Gilead Sciences, Inc.

Roger Paredes, MD, PhD
HIV Unit and IrsiCaixa AIDS Research Institute
Hospital Universitari Germans Trias I Pujol
Badalona, Spain

Dr Paredes has received research grants from and has served as an advisor for ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc.

Douglas D. Richman, MD (Group Vice Chair)
Professor of Pathology and Medicine
University of California San Diego
San Diego, California

Dr Richman has been a consultant to Antiva Biosciences, Gilead Sciences, Inc, and Viriome, Inc.

Robert W. Shafer, MD
Assistant Professor
Stanford University
Stanford, California

Dr Shafer has received research grants from Janssen Therapeutics, Vela Diagnostics, and InSilixa, Inc, and consulting fees from Abbott Diagnostics.

Annemarie M. Wensing, MD, PhD (Group Chair)
University Medical Center Utrecht
Utrecht, The Netherlands
University of the Witwatersrand
Johannesburg, South Africa

Dr Wensing has served on advisory boards for ViiV Healthcare, Merck & Co, Inc, Janssen Therapeutics, and Gilead Sciences, Inc, and has received research or unrestricted educational grants from Janssen Therapeutics, ViiV Healthcare, Merck & Co, Inc, and Gilead Sciences, Inc.